Memorial Hospital Research Laboratories

The Charles Rudin Lab

Share
Back to top

Research

Charles M. Rudin, MD, PhD
Charles M. Rudin, MD, PhD

Physician-scientist Charles M. Rudin, Chief of the Thoracic Oncology Service, leads research that focuses on the development and testing of novel therapeutic approaches to lung cancer in preclinical models including patient-derived xenografts. These studies are integrated with early phase clinical trials.

The Charles Rudin Lab Members

Featured News

Khaliq Sanda
Atypical Small Cell Carcinoma, a Rare Type Lung Cancer, Identified by MSK Research Team
A team of doctors and researchers at MSK have identified a new, rare type of small cell lung cancer that primarily affects younger people who have never smoked. Learn how one 19-year-old patient sparked a detective story.
In the Lab
Cyclotron engineer and nuclear pharmacist
New Imaging Detects Deadly Lung and Prostate Cancers, May Improve Treatment
Learn how a new imaging technique could improve detection and treatment of certain aggressive lung and prostate cancers.
Scientists Learn More about How Lung Cancer Becomes Resistant to Drugs
By switching from one cellular identity to another, lung cancer cells can evade targeted therapies. MSK scientists are trying to stop that from happening.

View All Featured News

Publications Highlights

Rekhtman et al., Chromothripsis-mediated small cell lung carcinoma. Cancer Discov 2024 (DOI: 10.1158/2159-8290.CD-24-0286).

Redin et al., SMARCA4 controls state plasticity in small cell lung cancer through regulation of neuroendocrine transcription factors and REST splicing. J Hematol Oncol 2024 (DOI: 10.1186/s13045-024-01572-3).

Quintanal-Villalonga et al., CDC7 inhibition impairs neuroendocrine transformation in lung and prostate tumors through MYC degradation. Signal Transduct Target Ther 2024 (DOI: 10.1038/s41392-024-01908-y).

Rudin et al., Clinical benefit from immunotherapy in patients with SCLC is associated with tumor capacity for antigen presentation. J Thorac Oncol 2023 (DOI: 10.1016/j.jtho.2023.05.008).

Quintanal-Villalonga A, Durani V, Sabet A, Redin E, Kawasaki K, Shafer M, Karthaus WR, Zaidi S, et al. Exportin 1 inhibition prevents neuroendocrine transformation through SOX2 down-regulation in lung and prostate cancers. Sci Transl Med. (2023)

View All Publications

People

Charles M. Rudin, MD, PhD

Charles M. Rudin, MD, PhD

  • Physician-scientist Charles Rudin focuses on the development and testing of novel therapeutic approaches to lung cancer in preclinical models.
  • MD, PhD, University of Chicago Pritzker School of Medicine
rudinc@mskcc.org
Email Address
View physician profile
Physician profile

Members

Fathema Uddin
Fathema Uddin

Graduate Student

Álvaro Quintanal Villalonga
Álvaro Quintanal Villalonga

Director, Translational Medicine-Oncology in AstraZeneca

Kelly Clarke
Kelly Clarke

Senior Program Manager

Barbara Mello, PhD
Barbara De Mello

Senior Research Assistant

Vidushi Durani
Vidushi Durani

Graduate Student

Laura Eibler

Graduate Student

Emelie Gezelius
Emelie Gezelius

Postdoctoral Fellow

Rishika Giri

Research Technician

Kenta Kawasaki
Kenta Kawasaki

Research Associate

Dennis Kinyua
Dennis Kinyua

Research Technician

Yonit Lavin

Instructor

Jake June-Koo Lee

Postdoctoral Fellow

Jin Lee

Postdoctoral Fellow

Parvathy Manoj
Parvathy Manoj

Lab Manager

Jorge Nuñez

Graduate Student

Esther Redin Resano
Esther Redin Resano

Assistant Member and Lab Co-Director

Amin Sabet

Graduate Student

Sohrab Salehi

Postdoctoral Fellow

Salomon Tendler
Salomon Tendler

Research Fellow

Zhanyu Wang
Zhanyu Wang

Graduate Research Assistant

Hong Zhong

Research Assistant

Lab Alumni
Viola Allaj
Viola Allaj

Research Associate, Pfizer Inc.

Metamia Ciampricotti
Metamia Ciampricotti

Medical Science Liaison, Tempus AI

John Poirier
John T. Poirier

Assistant Professor, Director, Preclinical Therapeutics Program, Perlmutter Cancer Center, NYU Langone Health

Joseph Chan
Joseph Chan

Assistant Member

Eric Gardner
Eric Gardner

Postdoctoral Research Fellow, Harold Varmus Lab, WCMC

Christopher Hulton, BS, MS
Christopher Hulton

Senior Scientist, Drug Discovery Biology, Treeline Biosciences, Cambridge, MA

Corrin Wohlhieter
Corrin Wohlhieter

Senior Associate, Clarion Life Sciences

James Laird
James Laird

Medical Resident, Yale School of Medicine

Pictured: Benjamin Lok
Benjamin Lok

Clinician-Scientist, Princess Margaret Cancer Centre and Assistant Professor of Radiation Oncology, University of Toronto

Nisarg Shah
Nisarg Shah

Lab Manager, University of Pennsylvania

Andrew Chow
Andrew Chow

Clinical Director in Oncology Early Development, Merck

Emily Costa

Postdoctoral Fellow, Rockefeller University

W. Victoria Lai
Victoria Lai

Senior Global Development, Late Oncology Lung, Astra Zeneca

Hirokazu Taniguchi
Hirokazu Taniguchi

Assistant professor, Nagasaki University Hospital, Department of Respiratory Medicine

Rebecca Caeser
Rebecca Caeser

Senior Scientist, National Cancer Center, Singapore

Arielle Elkrief

Assistant Professor & Clinician Scientist, University of Montreal; Co-Director CHUM Microbiome Centre

Jaspers Janneke
Janneke Jaspers

Technology Transfer Officer, Starfish Innovations

Michael Liu
Michael Liu

Research Technician

Linde Miles
Linde Miles

Assistant Professor, University of Cincinnati

Evelyn Nguyen

Consultant, Boston Consulting Group

Harsha Sridhar
Harsha Sridhar

Graduate Student, Francis Crick Institute

Kathryn M. Tully
Kathryn M. Tully

Scientist 1 at Ratio Therapeutics

Lab Affiliations

Open Positions

To learn more about available postdoctoral opportunities, please visit our Career Center

To learn more about compensation and benefits for postdoctoral researchers at MSK, please visit Resources for Postdocs

Career Opportunities

Apply now

Get in Touch

Disclosures

Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.

MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.

Charles M. Rudin discloses the following relationships and financial interests:

  • AbbVie
    Professional Services and Activities
  • Amgen
    Professional Services and Activities
  • Boehringer Ingelheim
    Professional Services and Activities
  • D2G Oncology
    Professional Services and Activities
  • Daiichi Sankyo
    Intellectual Property Rights
  • Earli Inc.
    Equity
  • Harpoon Therapeutics, Inc.
    Professional Services and Activities
  • Jazz Pharmaceuticals
    Professional Services and Activities
  • Mariana Oncology, Inc.
    Professional Services and Activities
  • Scorpion Therapeutics, Inc.
    Professional Services and Activities
  • Treeline Biosciences, Inc.
    Professional Services and Activities

The information published here is a complement to other publicly reported data and is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.

This page and data include information for a specific MSK annual disclosure period (January 1, 2023 through disclosure submission in spring 2024). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at ecoi@mskcc.org.


View all disclosures

Related topics: